Board Meeting14 Aug 2026, 07:42 pm
Gufic Biosciences Board Approves Q1 FY27 Unaudited Results
AI Summary
Gufic Biosciences Ltd announced that its Board of Directors, in a meeting held on August 14, 2026, approved the unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The results were presented on both standalone and consolidated bases, along with the limited review report. Additionally, the Board approved the incorporation of a subsidiary in the Philippines and an investment in its equity share capital, subject to regulatory approvals. The meeting commenced at 5:00 p.m. and concluded at 6:10 p.m.
Key Highlights
- Board approved unaudited Q1 FY27 financial results.
- Results were declared on standalone and consolidated basis.
- Company to incorporate a subsidiary in the Philippines.
- Investment in the new subsidiary's equity capital approved.
- Regulatory formalities for subsidiary incorporation are pending.
Price Impact
More from GUFICBIO